연구동향 분석

종설 : 만성 C형 간염 치료의 최근 발전

김태헌 ( Tae Hun Kim ) 이준성 ( June Sung Lee ) 2014년

논문상세정보
인용/피인용
' 종설 : 만성 C형 간염 치료의 최근 발전' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • chronic hepatitis c
  • treatement
  • 만성 c형 간염
  • 치료
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
205 0

0.0%

' 종설 : 만성 C형 간염 치료의 최근 발전' 의 참고문헌

  • Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
    Scheel TK Nat Med 19 : 837 ~ 849 - [2013]
  • Treatment of HCV infection by targeting microRNA
    Janssen HL N Engl J Med 368 : 1685 ~ 1694 - [2013]
  • Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
    Conteduca V J Infect 68 : 1 ~ 20 - [2014]
  • The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
    Bartenschlager R Nat Rev Microbiol 11 : 482 ~ 496 - [2013]
  • Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM N Engl J Med 364 : 2405 ~ 2416 - [2011]
  • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV Lancet 381 : 2100 ~ 2107 - [2013]
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E Lancet Infect Dis 13 : 401 ~ 408 - [2013]
  • Sofosbuvir for previously untreated chronic hepatitis C infection
    Lawitz E N Engl J Med 368 : 1878 ~ 1887 - [2013]
  • Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial
    Zeuzem S Hepatology 58 : 733A ~ - [2013]
  • Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
    Forns X Gastroenterology [2014]
  • Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial
    Manns M J Hepatol 58 : S568 ~ [2013]
  • Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial
    Jacobson I J Hepatol 58 : S574 ~ - [2013]
  • Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the aviator study
    Knowdley KV J Hepatol 58 : S2 ~ [2013]
  • SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study
    Jacobson IM Hepatology 58 : 1379A ~ - [2013]
  • Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
    Koff RS Aliment Pharmacol Ther 39 : 478 ~ 487 - [2014]
  • Recommendations for Testing, Managing, and Treating Hepatitis C
    American Association for the Study of Liver Diseases and the Infectious Diseases Society of America American Association for the Study of Liver Diseases and the Infectious Diseases Society of America
  • Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
    Suzuki F J Clin Virol 54 : 352 ~ 354 - [2012]
  • Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy
    Kim TH Intervirology 48 : 230 ~ 238 - [2005]
  • Novel therapeutic approaches for hepatitis C
    Au JS Clin Pharmacol Ther 95 : 78 ~ 88 - [2014]
  • Isolation of a cDNA clone derived from a blood-borne nonA, nonB viral hepatitis genome
    Choo QL Science 244 : 359 ~ 362 - [1989]
  • Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial
    Sulkowski MS Hepatology 57 : 2143 ~ 2154 - [2013]
  • Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
    Sulkowski MS Hepatology 57 : 2155 ~ 2163 - [2013]
  • Faldaprevir and deleobuvir for HCV genotype 1 infection
    Zeuzem S N Engl J Med 369 : 630 ~ 639 - [2013]
  • Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
    Zeuzem S Antivir Ther 18 : 1015 ~ 1019 - [2013]
  • Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
    Ali A ACS Chem Biol 8 : 1469 ~ 1478 [2013]
  • Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
    Chen J Gastroenterology 144 : 1450 ~ 1455 - [2013]
  • Boceprevir for untreated chronic HCV genotype 1 infection
    Poordad F N Engl J Med 364 : 1195 ~ 1206 - [2011]